RRM1单核苷酸多态性与非小细胞肺癌患者对吉西他滨化疗敏感性的相关性研究
x

请在关注微信后,向客服人员索取文件

篇名: RRM1单核苷酸多态性与非小细胞肺癌患者对吉西他滨化疗敏感性的相关性研究
TITLE:
摘要: 目的:探讨核苷酸还原酶M1亚基(RRM1)的单核苷酸多态性(SNPs)与非小细胞肺癌(NSCLC)患者对吉西他滨化疗敏感性的相关性。方法:选取2014年8月-2016年7月我院NSCLC初治患者96例,均接受以吉西他滨为基础的两药联合化疗方案,连续化疗至少2个周期(每28 d为1个周期)。以完全缓解、部分缓解的患者总数与受试患者总数的比值来计算化疗敏感率;采用聚合酶链反应和直接测序法检测其RRM1基因型;分析患者不同基因型与化疗敏感性的相关性。结果:RRM1-37C>A的CC、CA、AA基因型分布频率分别为35.42%、52.08%、12.50%,-524C>T的CC、CT、TT基因型分布频率分别为18.75%、37.50%、43.75%,各基因型分布频率均符合Hardy-Weinberg平衡(P>0.05)。96例NSCLC患者的化疗敏感率为37.50%。患者的年龄、性别、民族、吸烟与否、TNM分期、病理类型、化疗方案和美国东部肿瘤协作组评分与化疗敏感性无关(P>0.05)。RRM1(-37CA)+(-524CT)、(-37CC)+(-524TT)基因型患者的化疗敏感率(57.14%、39.39%)均显著高于其他基因型患者(10.71%),差异均有统计学意义(P<0.05);而RRM1(-37CA)+(-524CT)与(-37CC)+(-524TT)基因型患者的化疗敏感率比较,差异无统计学意义(P>0.05)。结论:NSCLC患者RRM1的SNPs可作为评价吉西他滨化疗敏感性的预测因子,RRM1(-37CA)+(-524CT)和(-37CC)+(-524TT)基因型患者对该类化疗方案具有更高的敏感性。
ABSTRACT: OBJECTIVE: To investigate the correlation between ribonucleotide reductase M1 subunit (RRM1) single nucleotide polymorphisms (SNPs) and chemotherapy sensitivity of patients with non-small cell lung cancer (NSCLC) for gemcitabine. METHODS: A total of 96 NSCLC patients receiving primary treatment selected from our hospital during Aug. 2014-Jul. 2016 were all accepted gemcitabine-based two-drug chemotherapy plan, with continuous treatment for at least 2 cycles (28 d as a cycle). Chemotherapy sensitivity rate was calculated by using the ratio of the sum of patients with complete response and partial response to the sum of test patients. RRM1 genotype was tested by PCR and direct sequencing. The correlation between different genotypes and chemotherapy sensitivity was analyzed. RESULTS: Distribution frequency of RRM1-37C>A CC, CA, AA genotype were 35.42%, 52.08%, 12.50%, respectively; distribution frequency of -524C>T CC, CT, TT genotype were 18.75%, 37.50%, 43.75%, respectively. The frequency of each genotype was in the line with Hardy-Weinberg equilibrium (P>0.05). Chemotherapy sensitivity rate of 96 NSCLC patients was 37.50%. The patient’s age, sex, ethnicity, smoking or not, TNM stage, pathological type, chemotherapy plan, and the Eastern American Oncology Collaboration score were not associated with chemotherapy sensitivity (P>0.05). Chemotherapy sensitivity rates of RRM1(-37CA)+(-524CT)genotype and (-37CC)+(-524TT) genotype patients (57.14%, 39.39%) were significantly higher than those of other genotype patients (10.71%), with statistical significance (P<0.05). There was no statistical significance in chemotherapy sensitivity rate between RRM1(-37CA)+(-524CT) and (-37CC)+(-524TT)genotype patients. CONCLUSIONS: In NSCLC patients, the SNPs of RRM1 can be used as predictive factor for the sensitivity of gemcitabine chemotherapy, and RRM1(-37CA)+(-524CT) and(-37CC)+(-524TT) genotype patients have higher sensitivity to this type of chemotherapy.
期刊: 2017年第28卷第35期
作者: 孟玲利,李晶,王艳娜,程艳芳,王慧,李娜,巩平
AUTHORS: MENG Lingli,LI Jing,WANG Yanna,CHENG Yanfang,WANG Hui,LI Na,GONG Ping
关键字: 非小细胞肺癌;核苷酸还原酶M1亚基;单核苷酸多态性;吉西他滨;化疗敏感性
KEYWORDS: Non-small cell lung cancer; Ribonucleotide reductase M1 subunit; Single nucleotide polymorphisms; Gemcitabine; Chemotherapy sensitivity
阅读数: 189 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!